PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Experimental strategies have long been applied for in vitro or in vivo evaluation of the effect of transporters and/or enzymes on the bioavailability. However, the lack of specific inhibitors or inducers of transporters and enzymes and the multiplicity of nuclear receptors in gene regulation and cross-talk have led to compromised assessments of these effects in vivo. These and other causes have resulted in confusion and controversy in transporter-enzyme interplay. In this review, physiologically-based pharmacokinetic (PBPK) intestinal and liver models are utilized to predict the contributions of enzymes and transporters on intestinal availability (FI) and hepatic availability (FH), with the aim to fully understand the impact of these variables on bioavailability (Fsys) in vivo. We emphasize the often overlooked impact of influx and efflux clearances, and apply the PBPK models and their solutions to examine individual organ clearances of the intestine and liver. In order to accurately predict oral bioavailability, these organ models are incorporated into the whole body PBPK model, and additional complicated scenarios such as segmental differences and zonal heterogeneity of transporters and enzymes in the intestine and liver, and segregated blood flow patterns of the intestine are further discussed. The sequential metabolism of a drug to form primary and secondary metabolites in the first-pass organs is considered in PBPK modeling, revealing that the segregated flow model (SFM) of the intestine is more appropriate than the traditional PBPK intestinal model (TM). Examples are included to highlight the potential application of these PBPK models on the quantitative prediction of bioavailability. Keywords: Physiologically-based pharmacokinetic (PBPK) model, bioavailability, enzyme, transporter, liver, intestine, metabolism, excretion, area under the curve (AUC), clearance, PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism, FH, Fsys, SFM, TM, GI, Lipophilic drugs, carboxylesterases, methyltransferase, P450s, cyclosporine, midazolam, nifedipine, enterocyte, hepatocyte, MCT1, MRP2, BCRP, OATPs, OCT1, BSEP, CAT, ACAT, Vmax, Km, PBPK, FI, Simcyp, Esterase/ enalaprilat, methyldopa sulfate, IVIVE, PLS, ANN, EHBR, availability, Heterogeneity, Zonal Liver Model, area under the curve, ADME, Sulfatase, ENZYMES, M3G, DPD
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651 · cited 3×
“This model consists of a stomach compartment, followed by seven compartments, aligned in series, in the small intestine for transit and absorption of drug and a colon compartment, with implementation of the Gastroplus® Software for the prediction of drug absorption [13].”
BackgroundMethodInfluentialBarter, Z., Bayliss, M., Beaune, P., Boobis, A., Carlile, D., Edwards, R., Brian Houston, J., Lake, B., Lipscomb, J., Pelkonen, O., et al. (2007) · Current Drug Metabolism · doi:10.2174/138920007779315053 · Cited by 459
Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes
Rodgers, T., & Rowland, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9210-3 · Cited by 420
Prediction of Intestinal First-Pass Drug Metabolism
Yang, J., Jamei, M., Yeo, K., Tucker, G., & Rostami-Hodjegan, A. (2007) · Current Drug Metabolism · doi:10.2174/138920007782109733 · Cited by 366
Riches, Z., Stanley, E. L., Bloomer, J. C., & Coughtrie, M. W. H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028399 · Cited by 365 · cited 1×
“The small intestine contains the largest overall amount of SULT of any of the tissues, with SULT1B1 as being the major enzyme (36%), closely followed by SULT1A3 (31%), and SULT1A1, SULT1E1, and SULT2A1 (19, 8, and 6%, respectively), whereas in the liver, SULT1A1 is the major enzyme (>50% of total in the liver), follow…”
BackgroundA Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
De Buck, S. S., Sinha, V. K., Fenu, L. A., Nijsen, M. J., Mackie, C. E., & Gilissen, R. A. H. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015644 · Cited by 256
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223
Apical/Basolateral Surface Expression of Drug Transporters and its Role in Vectorial Drug Transport
Ito, K., Suzuki, H., Horie, T., & Sugiyama, Y. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-6810-2 · Cited by 174
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M. (2007) · Xenobiotica · doi:10.1080/00498250701534885 · Cited by 115
Organ Clearance Concepts: New Perspectives on Old Principles
Sirianni, G. L., & Pang, K. S. (1997) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1025792925854 · Cited by 89 · cited 1×
“Reduced metabolism occurs when secretion is enhanced (for example, induction of P-gp), and increased metabolism occurs when secretion is decreased [7, 38, 42, 80], an observation attributed to the competing nature of these pathways for the drug concentration in the intestinal cell that drives the metabolic or excretor…”
BackgroundSelf-citationAdvanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts
Pang, K. S., Weiss, M., & Macheras, P. (2007) · The AAPS Journal · doi:10.1208/aapsj0902030 · Cited by 61 · cited 2×
“In order to accommodate these heterogeneous factors, the zonal liver model (ZLM) that describes the periportal (pp), midzonal (mz), and perivenous (pv) regions relates to zones 1, 2, and 3 of the liver acinus, the simplest microcirculatory unit [138], has been used to accommodate the heterogeneity in basolateral influ…”
BackgroundSelf-citation
Cited by
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Sager, J. E., Yu, J., Ragueneau-Majlessi, I., & Isoherranen, N. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065920 · Cited by 518
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Self-citationBarton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
Heikkinen, A. T., Fowler, S., Gray, L., Li, J., Peng, Y., Yadava, P., Railkar, A., & Parrott, N. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300692k · Cited by 20
Metadata
- Authors
- Fan, J., Chen, S., C.Y. Chow, E., & Sandy Pang, K.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-11-01
- Volume
- 11
- Issue
- 9
- Pages
- 743-761
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2116774028
- Cited by
- 62
- References
- 14
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.